Post-acute COVID-19 in three doses vaccinated autoimmune rheumatic diseases patients: frequency and pattern of this condition

Advances in Rheumatology

Research

Victor Hugo Ferreira e Léda¹  Luisa Sacchi de Camargo Correia¹  Artur Fonseca Sartori¹  Danieli Castro Oliveira Andrade¹  Carolina Torres Ribeiro¹  Samuel Katsuyuki Shinjo¹  Leonard de Vinci Kanda Kupa¹  Percival Degrava Sampaio-Barros¹  Victor Adriano de Oliveira Martins¹  Carolina Campagnoli Machado Freire Martins¹  Eduardo Ferreira Borba Neto¹  Sandra Gofinet Pasoto¹  Emily Figueiredo Neves Yuki¹  Filipe Waridel¹  Ana Cristina Medeiros-Ribeiro¹  Eloisa Bonfa¹  Joaquim Ivo Vasques Dantas Landim¹  Carla Gonçalves Schahin Saad¹  Clovis Artur Silva²  Nadia Emi Aikawa² 

[1] Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira César, 01246-903, São Paulo, SP, Brazil;Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira César, 01246-903, São Paulo, SP, Brazil;Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil;

关键词: Autoimmune diseases;    COVID-19;    Long COVID-19;    Post-COVID-19 syndrome;   

DOI  :  10.1186/s42358-023-00309-z

 received in 2023-02-22, accepted in 2023-05-29,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundData on post-acute COVID-19 in autoimmune rheumatic diseases (ARD) are scarce, focusing on a single disease, with variable definitions of this condition and time of vaccination. The aim of this study was to evaluate the frequency and pattern of post-acute COVID-19 in vaccinated patients with ARD using established diagnosis criteria.MethodsRetrospective evaluation of a prospective cohort of 108 ARD patients and 32 non-ARD controls, diagnosed with SARS-CoV-2 infection (RT-PCR/antigen test) after the third dose of the CoronaVac vaccine. Post-acute COVID-19 (≥ 4 weeks and > 12 weeks of SARS-CoV-2 symptoms) were registered according to the established international criteria.ResultsARD patients and non-ARD controls, balanced for age and sex, had high and comparable frequencies of ≥ 4 weeks post-acute COVID-19 (58.3% vs. 53.1%, p = 0.6854) and > 12 weeks post-acute COVID-19 (39.8% vs. 46.9%, p = 0.5419). Regarding ≥ 4 weeks post-acute COVID-19, frequencies of ≥ 3 symptoms were similar in ARD and non-ARD controls (54% vs. 41.2%, p = 0.7886), and this was also similar in > 12 weeks post-acute COVID-19 (68.3% vs. 88.2%, p = 0.1322). Further analysis of the risk factors for ≥ 4 weeks post-acute COVID-19 in ARD patients revealed that age, sex, clinical severity of COVID-19, reinfection, and autoimmune diseases were not associated with this condition (p > 0.05). The clinical manifestations of post-acute COVID-19 were similar in both groups (p > 0.05), with fatigue and memory loss being the most frequent manifestations.ConclusionWe provide novel data demonstrating that immune/inflammatory ARD disturbances after third dose vaccination do not seem to be a major determinant of post-acute COVID-19 since its pattern is very similar to that of the general population. Clinical Trials platform (NCT04754698).

【 授权许可】

CC BY   
© The Author(s) 2023. corrected publication 2023

【 图 表 】

40517_2023_252_Article_IEq35.gif